Cytosorbents Medical Inc
CAGE Code: 5E0N2
NCAGE Code: 5E0N2
Status: Active
Type: Manufacturer
Dun & Bradstreet (DUNS): 830014077
Summary
Cytosorbents Medical Inc is an Active Manufacturer with the Cage Code 5E0N2 and is tracked by Dun & Bradstreet under DUNS Number 830014077..
Address
305 College Road East
Princeton NJ 08540-6608
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Custom Mfg Services Inc Axiom Digital Inc Topps Electronic Services Inc Crossley Machine Co All Star Fire Protection Premier Concrete Inc Prairie Restorations Inc Alfa Systems Bracco Diagnostics Inc. Quarks Advantage Corp Book Sellers Inc Permevo Consulting Inc Premier Fastener Co Hamner Electronics Co Inc Anomaly Detection Systems Parsons Brinkerhoff Princeton Braillists Northington-Doviak Inc Advent Imaging Inc Key-Note Music Inc
Frequently Asked Questions (FAQ) for CAGE 5E0N2
- What is CAGE Code 5E0N2?
- 5E0N2 is the unique identifier used by NATO Organizations to reference the physical entity known as Cytosorbents Medical Inc located at 305 College Road East, Princeton NJ 08540-6608, United States.
- Who is CAGE Code 5E0N2?
- 5E0N2 refers to Cytosorbents Medical Inc located at 305 College Road East, Princeton NJ 08540-6608, United States.
- Where is CAGE Code 5E0N2 Located?
- CAGE Code 5E0N2 is located in Princeton, NJ, USA.
Contracting History for CAGE 5E0N2 Most Recent 25 Records
- FA864923P0777
- Novel Sorbent Technology For The Rapid Treatment Of Acute Joint Injury And Inflammation
- 12 May 2023
- Novel Sorbent Technology For The Rapid Treatment Of Acute Joint Injury And Inflammation
- Fa8649 Usaf Sbir Sttr Contracting
- Department Of Defense (Dod)
- $74,918.00
- Department Of Defense (Dod)
- FA864923P0420
- Novel Oral Sorbent Therapy For The Prevention And Treatment Of Travelers Diarrhea
- 1 Nov 2022
- Novel Oral Sorbent Therapy For The Prevention And Treatment Of Travelers Diarrhea
- Fa8649 Usaf Sbir Sttr Contracting
- Department Of Defense (Dod)
- $74,955.00
- Department Of Defense (Dod)
- W81XWH22C0046
- Dha Sbir Phase Iii Proposal Jw210458 Integrating Isoagglutinin Reduction For A Universal Dried Plasma Product For Battlefield And First Responder Use
- 4 May 2023
- Dha Sbir Phase Iii Proposal Jw210458 Integrating Isoagglutinin Reduction For A Universal Dried Plasma Product For Battlefield And First Responder Use
- Army Med Res Acq Activity
- Department Of Defense (Dod)
- $4,292,641.00
- Department Of Defense (Dod)
- W81XWH22C0046
- Award Of Cytosorbents Dha Sbir Ph Iii Med R&D Contract For "Integrating Isoagglutinin Reduction For A Universal Dried Plasma Product For Battlefield And First Responder Use"
- 17 Aug 2022
- Award Of Cytosorbents Dha Sbir Ph Iii Med R&D Contract For "Integrating Isoagglutinin Reduction For A Universal Dried Plasma Product For Battlefield And First Responder Use"
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $4,292,641.00
- Department Of Defense (Dod)
- W81XWH22C0046
- Revised Sow Incorporated Into Cytosorbents Dha Sbir Phase Ii Medical R&D Contract For "Integrating Isoagglutinin Reduction For A Universal Dried Plasma Product For Battlefield And First Responder Use"
- 12 Sep 2022
- Revised Sow Incorporated Into Cytosorbents Dha Sbir Phase Ii Medical R&D Contract For "Integrating Isoagglutinin Reduction For A Universal Dried Plasma Product For Battlefield And First Responder Use"
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $4,292,641.00
- Department Of Defense (Dod)
- W81XWH22C0046
- Dha Sbir Phase Iii Proposal Jw210458 Integrating Isoagglutinin Reduction For A Universal Dried Plasma Product For Battlefield And First Responder Use
- 22 Feb 2023
- Dha Sbir Phase Iii Proposal Jw210458 Integrating Isoagglutinin Reduction For A Universal Dried Plasma Product For Battlefield And First Responder Use
- Army Med Res Acq Activity
- Department Of Defense (Dod)
- $4,292,641.00
- Department Of Defense (Dod)
- W81XWH21C0045
- Medical Research And Development Contract Dha Sbir Sequential Ph Ii Proposal No. H2s-0011 Titled Investigation Of A Potassium Adsorber For The Treatment Of Hyperkalemia Induced By Traumatic Injury And Acute Kidney Injury In Austere Medicine.
- 14 Sep 2022
- Medical Research And Development Contract Dha Sbir Sequential Ph Ii Proposal No. H2s-0011 Titled Investigation Of A Potassium Adsorber For The Treatment Of Hyperkalemia Induced By Traumatic Injury And Acute Kidney Injury In Austere Medicine.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,499,987.16
- Department Of Defense (Dod)
- W81XWH21C0045
- Medical Research And Development Contract Dha Sbir Sequential Ph Ii Proposal No. H2s-0011 Titled Investigation Of A Potassium Adsorber For The Treatment Of Hyperkalemia Induced By Traumatic Injury And Acute Kidney Injury In Austere Medicine.
- 19 Apr 2021
- Medical Research And Development Contract Dha Sbir Sequential Ph Ii Proposal No. H2s-0011 Titled Investigation Of A Potassium Adsorber For The Treatment Of Hyperkalemia Induced By Traumatic Injury And Acute Kidney Injury In Austere Medicine.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,499,987.16
- Department Of Defense (Dod)
- W81XWH21C0045
- Medical Research And Development Contract Dha Sbir Sequential Ph Ii Proposal No. H2s-0011. Modification P00002 Change Payment Dodaac.
- 29 Jul 2021
- Medical Research And Development Contract Dha Sbir Sequential Ph Ii Proposal No. H2s-0011. Modification P00002 Change Payment Dodaac.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,499,987.16
- Department Of Defense (Dod)
- W81XWH21C0045
- Dha Sbir Sequential Ph Ii - H2s-0011. Per Section 711 Of The 2019 Ndaa, Usamraa Transferred To Dha 10/1/2022. Twelve-Month No-Cost Extension.
- 7 Feb 2023
- Dha Sbir Sequential Ph Ii - H2s-0011. Per Section 711 Of The 2019 Ndaa, Usamraa Transferred To Dha 10/1/2022. Twelve-Month No-Cost Extension.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,499,987.16
- Department Of Defense (Dod)
- W81XWH21C0045
- Medical Research And Development Contract Dha Sbir Sequential Ph Ii Proposal No. H2s-0011 Titled Investigation Of A Potassium Adsorber For The Treatment Of Hyperkalemia Induced By Traumatic Injury And Acute Kidney Injury In Austere Medicine.
- 14 Jul 2021
- Medical Research And Development Contract Dha Sbir Sequential Ph Ii Proposal No. H2s-0011 Titled Investigation Of A Potassium Adsorber For The Treatment Of Hyperkalemia Induced By Traumatic Injury And Acute Kidney Injury In Austere Medicine.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,499,987.16
- Department Of Defense (Dod)
- W81XWH20C0087
- Medical Research And Development Contract Dha Sbir Phase Ii Proposal No. H2s-0005 Titled Development Of An Effective Adsorber To Remove Anti-A And Anti-B Antibodies From Plasma For Transfusion. Modification P00001 Cor Change.
- 25 Oct 2021
- Medical Research And Development Contract Dha Sbir Phase Ii Proposal No. H2s-0005 Titled Development Of An Effective Adsorber To Remove Anti-A And Anti-B Antibodies From Plasma For Transfusion. Modification P00001 Cor Change.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,098,588.51
- Department Of Defense (Dod)
- W81XWH20C0087
- Dha Sbir Phase Ii An91 Medical R&D Contract H2s-0005 (Months 1-12)Nce For Development Of An Effective Adsorber To Remove Anti-A And Anti-B Antibodies From Plasma For Transfusion
- 13 Sep 2022
- Dha Sbir Phase Ii An91 Medical R&D Contract H2s-0005 (Months 1-12)Nce For Development Of An Effective Adsorber To Remove Anti-A And Anti-B Antibodies From Plasma For Transfusion
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,098,588.51
- Department Of Defense (Dod)
- W81XWH20C0087
- Dha Sbir Phase Ii H2s-0005 "Development Of An Effective Adsorber To Remove Anti-A And Anti-B Antibodies From Plasma For Transfusion"
- 22 Sep 2023
- Dha Sbir Phase Ii H2s-0005 "Development Of An Effective Adsorber To Remove Anti-A And Anti-B Antibodies From Plasma For Transfusion"
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,098,588.51
- Department Of Defense (Dod)
- W81XWH20C0050
- No Cost Extension To The Award Of Cytosorbents' Dha Sttr Phase Iii Medical R&D Contract For "Development Of A Highly Efficient Adsorber To Remove Anti-A And Anti-B Antibodies From Blood And Plasma For Transfusion"
- 24 May 2022
- No Cost Extension To The Award Of Cytosorbents' Dha Sttr Phase Iii Medical R&D Contract For "Development Of A Highly Efficient Adsorber To Remove Anti-A And Anti-B Antibodies From Blood And Plasma For Transfusion"
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $2,897,172.00
- Department Of Defense (Dod)
- W81XWH20C0050
- Cytosorbents Dha Sttr Rif Phase Iii - Dhp15b-001-P-6144 Development Of A Highly Efficient Adsorber To Remove Anti-A And Anti-B Antibodies From Blood And Plasma For Transfusion
- 6 Jun 2023
- Cytosorbents Dha Sttr Rif Phase Iii - Dhp15b-001-P-6144 Development Of A Highly Efficient Adsorber To Remove Anti-A And Anti-B Antibodies From Blood And Plasma For Transfusion
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $2,897,172.00
- Department Of Defense (Dod)
- W81XWH20C0050
- Cor Change To The Award Of Cytosorbents Dha Sttr Phase Iii Medical R&D Contract For "Development Of A Highly Efficient Adsorber To Remove Anti-A And Anti-B Antibodies From Blood And Plasma For Transfusion"
- 5 May 2021
- Cor Change To The Award Of Cytosorbents Dha Sttr Phase Iii Medical R&D Contract For "Development Of A Highly Efficient Adsorber To Remove Anti-A And Anti-B Antibodies From Blood And Plasma For Transfusion"
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $2,897,172.00
- Department Of Defense (Dod)
- FA865019C6065
- K+Ontrol Renal Support System For Reduction Of Hyperkalemia - Period Of Performance Extension
- 30 Jun 2021
- K+Ontrol Renal Support System For Reduction Of Hyperkalemia - Period Of Performance Extension
- Fa8650 Usaf Afmc Afrl Pzl Rak Rxk
- Department Of Defense (Dod)
- $2,959,747.00
- Department Of Defense (Dod)
- W81XWH12C0038
- 2 Month No-Cost Extension To Allow For The Continuation Of The Porcine Studies.
- 6 Jul 2017
- 2 Month No-Cost Extension To Allow For The Continuation Of The Porcine Studies.
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,246,262.22
- Department Of Defense (Dod)
- W81XWH12C0038
- Final Deobligation To The Award Of Cytosorbents' Army Sbir Phase Ii Medical R&D Contract For "Investigation Of Cytosorb Cytokine And Myoglobin Removal In The Treatment Of Trauma"
- 24 Jun 2021
- Final Deobligation To The Award Of Cytosorbents' Army Sbir Phase Ii Medical R&D Contract For "Investigation Of Cytosorb Cytokine And Myoglobin Removal In The Treatment Of Trauma"
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $1,246,262.12
- Department Of Defense (Dod)
- W81XWH17C0142
- Dha Sbir Ph Ii H2-0210 Ulo
- 18 Feb 2022
- Dha Sbir Ph Ii H2-0210 Ulo
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $999,871.34
- Department Of Defense (Dod)
- W81XWH17C0142
- Igf::Ot::Igf Dha Sbir Phase Ii Proposal H2-0210
- 20 Sep 2017
- Igf::Ot::Igf Dha Sbir Phase Ii Proposal H2-0210
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $999,871.34
- Department Of Defense (Dod)
- W81XWH17C0053
- Igf::Ot::Igf Dhp Sbir Phase Ii #H2-0204
- 12 May 2017
- Igf::Ot::Igf Dhp Sbir Phase Ii #H2-0204
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $999,070.00
- Department Of Defense (Dod)